Omnicell, Inc. (OMCL) SEC Filings & Earnings Calls

Tariff exposure

“The scope, rate, duration, legality and implementation of existing or future tariffs remain uncertain, and additional tariff measures, changes to existing exclusions, retaliatory trade actions, litigation outcomes, refund processes or other changes in U.S. or foreign trade policy could increase our costs, disrupt our supply chain, affect customer demand or r” · word for word

Healthcare policy pressure

“The 2025–2028 healthcare landscape, however, faces significant fiscal headwinds driven by sweeping changes in health policy, specifically the One Big Beautiful Bill Act (“OBBBA”), which is expected to result in a $910 billion Medicaid spending reduction across states.” · word for word

Customer budget constraints

“We also recognize that these challenges may impact the timing of contracting for, or implementation of, our products, solutions, or services.” · word for word

Annual recurring revenue guidance lowered due to longer development timelines for some growth opportunities.

“annual recurring revenue guidance to reflect certain growth opportunities that we now expect will take longer to develop than previously projected” · word for word

Product bookings guidance updated to reflect range of potential outcomes.

“updating our product bookings guidance to reflect our current assessment of the range of potential outcomes” · word for word

Potential shareholder dilution from increased equity plan shares.

“1,600,000 additional shares authorized under the Amended 2009 Plan.”

Tariff impact on cost of goods sold

“The increase in cost of product revenues has not increased proportionally with the increase in product revenues primarily due to the favorable impact of scale and efficiencies in installations as well as product and customer mix, partially offset by the impact of tariffs during the three months ended March 31, 2026.” · word for word

Concentration of cash with limited financial institutions

“As of March 31, 2026, a substantial portion of the Company’s cash and cash equivalents were held with a limited number of financial institutions and money market funds, which may expose the Company to concentration risk in the event of a failure or adverse condition affecting those entities.” · word for word

Dependence on capital spending cycles of health systems for new product adoption (Titan XT, OmniSphere)

“Customer engagement underway for Omnicell Titan XT and OmniSphere; health systems incorporating into longer-term capital planning cycles” · word for word

Negative TSR caps PSU payout

“The Company's total stockholder return for 2025 was less than zero, the percentage of the target number of PSUs eligible to be earned was capped at 100%.” · word for word

Non-GAAP EBITDA missed target

“the Company achieved a performance of 89.1% of target for non-GAAP EBITDA” · word for word

Product bookings declined 4% YoY, indicating potential slowdown in demand for connected devices and software licenses.

“Product bookings were $535 million compared to $558 million in prior year, a decrease of 4%.” · word for word

Product adoption risk; competitive market

“New product launch with no revenue projections; market acceptance uncertain”

Tariff exposure on imported components

“the U.S. imposed tariffs on a wide variety of products manufactured in multiple foreign jurisdictions, including China, Mexico, and Malaysia.” · word for word

Dependence on capital equipment budgets

“Our ability to grow revenues is dependent on our ability to continue to obtain orders from customers, which may be dependent upon customers’ capital equipment budgets and/or capital equipment approval cycles” · word for word

Timing of installations

“The timing of our product revenues for equipment is primarily dependent on when our customers’ schedules and/or staffing levels allow for installations.” · word for word

Convertible note maturity: repaid $175M principal in Q3 2025, reducing debt but using cash.

“repaid the remaining principal balance of $175 million of the convertible senior notes that matured on September 15, 2025” · word for word

Share repurchase: $62M spent on buybacks in Q3, reducing share count but using cash.

“repurchased approximately 1,987,000 shares of its common stock for an aggregate purchase price of approximately $62 million” · word for word